New hope for kids with kidney disease: drug trial targets protein leak
NCT ID NCT07024563
First seen Jan 06, 2026 · Last updated Jun 08, 2026 · Updated 20 times
Summary
This study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage. Participants will receive the drug through an IV and be monitored for safety and effectiveness over about 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGPalo Alto, California, 94304, United States
-
Research Site
RECRUITINGAurora, Colorado, 80045, United States
-
Research Site
RECRUITINGBeijing, 100045, China
-
Research Site
RECRUITINGShanghai, 201102, China
-
Research Site
RECRUITINGGenova, 16147, Italy
-
Research Site
RECRUITINGRoma, 00165, Italy
-
Research Site
RECRUITINGTorino, 10126, Italy
-
Research Site
RECRUITINGWakayama, 641-8510, Japan
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
RECRUITINGBarcelona, 8950, Spain
-
Research Site
RECRUITINGSeville, 41013, Spain
-
Research Site
RECRUITINGTaipei, 10002, Taiwan
-
Research Site
RECRUITINGTaoyuan, 333, Taiwan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.